home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

The 2012 London Regenerative Medicine Event

 
  November 21, 2011  
     
 
Euroscicon, United Kingdom
16 February 2012


9:00 – 9:45            Registration

 

9:45 – 10:00         Introduction by the Chair:  Professor Christopher J. Hewitt, Loughborough University, UK

 

10:00 – 10:20       Skeletal Stem Cells – Bridging the Gap in Bone Regeneration  from Cell Biology to Clinical Translation

Professor Richard OC Oreffo, University of Southampton, UK (morning speaking slot)

 

10:20 – 10:40       Translating Research Into Viable Clinical Treatments.  How to build on 60 years of patient focused clinical delivery

Dr Simon Ellison, National Blood Service, UK (morning speaking slot)

The criticality of managing the process from consent to patient.

•               Utilising open innovation partnerships can deliver treatments and revenue.

•               How to generate patient focused manufacturing and scale up.

•               Accessing validated national cold supply chains.

 

10:40 – 11:00       The future potential of cellular immunotherapy’s

Dr Mark Cobbold, The University of Birmingham¸UK

.

11:00 – 11:30       Speakers’ photo then mid-morning break and trade show

 

11:30  – 11:50      Improving the yield of pluripotent stem cell differentiation processess

                            Dr Farlan Veraitch, Department of Biochemical Engineering, University College London, UK

               

11:50  – 12:10      Scaling Red Blood Cell Manufacture from Cord Blood and Placenta Derived CD34+ Haematopoietic Stem Cells

Dr Robert Thomas,  Senior Lecturer, Associate Director EPSRC Centre for Innovative Manufacturing in Regenerative Medicine

The technology to expand and differentiate stem cells from human umbilical cord blood will potentially underpin the manufacture of a number of therapeutic cellular products, including erythrocytes and platelets. Such technology will overcome the logistical limitations associated with sourcing short shelf-life and disease screened voluntary blood donations. However, these cell products pose significant challenges in the development of economically scalable production systems and processes that are capable of consistent delivery of clinical quality cells.

As part of an international and multidisciplinary consortium of engineers and cell biologists led by Celgene Cellular Therapeutics, we have established key challenges and mitigating strategies for the production of erythrocytes at large scale from umbilical cord and placenta derived CD34+ cells. We have demonstrated a multi-stage expansion and differentiation process that integrates both established and novel technologies and cytokine supplementation schedules to consistently achieve high production densities of erythroid cells. We have further employed a new millilitre scale precision process development platform (AMBR, TAP Biosystems) to rigorously characterise critical elements of the production environment and identify factors determining cell expansion and quality (assessed through development of multiple erythroid markers including CD71, CD235a and Haemoglobin) and to reduce process cost.

In the near future the consortium anticipates further optimisation of the bioprocess and automated integration of downstream processing to facilitate clinical-scale production of a therapeutically effective red blood cell like product. The process development and control learning, and the key parameter ranges established, are likely to be transferable to other development programmes for regenerative cell products.

               

12:10– 12:30       Talk to be confirmed

Dr Annette Meeson, Institute of Human Genetics, Newcastle University, International Centre for Life, UK

 

12:30 – 13:30       Lunch and trade show

 

13:30 – 14:30       Question and Answer Session

Delegates will be asked to submit questions to a panel of experts.  Questions can be submitted before the event or on the day

 

14:30 – 15:00       Oral presentations

 

15:00  - 15:30       Afternoon Tea/Coffee  and  trade show

 

15:30 – 15:50       Regulation of Regenerative Medicine Products

Ms Alison Wilson, CellData Services, UK

•               Outline of the Advanced Therapy Medicinal Products Regulation

•               Other relevant legislation

•               Major regulatory issues in progressing from the lab to the clinic

 

15:50 – 16:10       Talk to be confirmed

Professor Julian B Chaudhuri, Professor of Biochemical & Biomedical Engineering, Centre for Regenerative Medicine, Department of Chemical Engineering, University of Bath, UK

 

16:10 – 16:30       Chairman’s summing up

 
 
Organized by: Euroscicon
Invited Speakers:

Continued improvement in the nation’s health depends upon the development of affordable and effective medicines and new therapeutic treatments. The last 20 years has seen the growth of a global healthcare industry based on human proteins produced in transformed mammalian cell lines, with a current market value of £30 billion/year. There is now an opportunity to replicate this growth in new industries using human stem cells in pharmaceutical and regenerative medicine applications. This meeting will focus on exploring the biological and engineering challenges which  lie ahead before cell based therapies can become an everyday reality.


 

 
Deadline for Abstracts: December 10th 2011
 
Registration: http://www.regonline.co.uk/regen2012
E-mail: sharacohen@euroscicon.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.